{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:13:38Z","timestamp":1790115218539,"version":"4.0.1"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Antiphospholipid syndrome (APS) is characterised by increased cardiovascular morbidity and mortality, related to thrombo-inflammatory and atherogenic mechanisms. We examined the achievement of traditional cardiovascular risk factor (CVRF) therapeutic goals in APS versus other high cardiovascular risk disorders such as rheumatoid arthritis (RA) and diabetes mellitus (DM), and trends over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>122 patients with APS (74 primary APS, female 68%, mean age 44.5\u00b111.3) were classified according to their first visit (2011\u20132015 and 2016\u20132020 APS subgroups, 61 patients in each subgroup) and matched 1:1 for age\/sex with patients with RA and DM. Cardiovascular risk was estimated by the Systemic Coronary Risk Evaluation, and the CVRF therapeutic targets were defined according to the European Society of Cardiology (ESC) guidelines. Individual and multiple CVRF control was compared between APS subgroups, and in APS versus RA and DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found a comparable or higher prevalence of CVRFs between APS and age-matched\/sex-matched patients with RA and DM but low CVRF target attainment in APS according to the ESC guidelines. Despite improving trends between 2011\u20132015 and 2016\u20132020, CVRF control in high\/very high-risk patients with APS was 12%, 18%, 24% and 35% for low-density lipoprotein, waist circumference, exercise and body mass index, respectively, and 59%\u201365% for triglycerides, high-density lipoprotein (HDL) and blood pressure, in 2016\u20132020 subgroup. CVRF control was worse in APS versus RA for smoking (p=0.014), HDL (p&lt;0.001), waist circumference (p=0.042) and five CVRFs (p=0.030), and versus DM for exercise (p=0.077). Similar results were found in the sensitivity analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Comparable prevalence of modifiable CVRFs to RA and DM but suboptimal CVRF target achievement was observed in APS, especially in high\/very high-risk patients, highlighting the need for CVRF management strategies.<\/jats:p><\/jats:sec>","DOI":"10.1136\/lupus-2021-000579","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T17:13:20Z","timestamp":1639761200000},"page":"e000579","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus"],"prefix":"10.1136","volume":"8","author":[{"given":"Eleana","family":"Bolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Tentolouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"key":"2024052109592122000_8.1.e000579.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2024052109592122000_8.1.e000579.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838"},{"key":"2024052109592122000_8.1.e000579.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.02.058"},{"key":"2024052109592122000_8.1.e000579.4","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/rheumatology\/keaa548","article-title":"Clinical value of amyloid-beta1-40 as a marker of thrombo-inflammation in antiphospholipid syndrome","volume":"60","author":"Tektonidou","year":"2021","journal-title":"Rheumatology"},{"key":"2024052109592122000_8.1.e000579.5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.medcli.2017.05.003","article-title":"Mechanisms of atherosclerosis and cardiovascular disease in antiphospholipid syndrome and systemic lupus erythematosus. new therapeutic approaches","volume":"149","author":"Lopez-Pedrera","year":"2017","journal-title":"Medicina Cl\u00ednica"},{"key":"2024052109592122000_8.1.e000579.6","article-title":"Growth differentiation factor 15 (GDF-15) as potential cardiovascular risk biomarker in antiphospholipid syndrome","volume":"4","author":"Tektonidou","year":"2021","journal-title":"Rheumatology"},{"key":"2024052109592122000_8.1.e000579.7","first-page":"1","article-title":"Cardiovascular risk factors in the antiphospholipid syndrome","volume":"2014","author":"da Silva","year":"2014","journal-title":"J Immunol Res"},{"key":"2024052109592122000_8.1.e000579.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016204"},{"key":"2024052109592122000_8.1.e000579.9","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307081847"},{"key":"2024052109592122000_8.1.e000579.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.7.607"},{"key":"2024052109592122000_8.1.e000579.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081194"},{"key":"2024052109592122000_8.1.e000579.12","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.thromres.2015.10.029","article-title":"Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response","volume":"136","author":"Saraiva","year":"2015","journal-title":"Thromb Res"},{"key":"2024052109592122000_8.1.e000579.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21701"},{"key":"2024052109592122000_8.1.e000579.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.10.004"},{"key":"2024052109592122000_8.1.e000579.15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/rheumatology\/keaa321","article-title":"Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study","volume":"60","author":"Panopoulos","year":"2021","journal-title":"Rheumatology"},{"key":"2024052109592122000_8.1.e000579.16","first-page":"1560","article-title":"Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals","volume":"31","author":"Gir\u00f3n-Gonz\u00e1lez","year":"2004","journal-title":"J Rheumatol"},{"key":"2024052109592122000_8.1.e000579.17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.thromres.2013.11.012","article-title":"Risk factors for arterial thrombosis in antiphospholipid syndrome","volume":"133","author":"Matyja-Bednarczyk","year":"2014","journal-title":"Thromb Res"},{"key":"2024052109592122000_8.1.e000579.18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS action cohort","volume":"49","author":"Radin","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2024052109592122000_8.1.e000579.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs092"},{"key":"2024052109592122000_8.1.e000579.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"2024052109592122000_8.1.e000579.21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/dom.13625","article-title":"Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: the diabetes collaborative registry","volume":"21","author":"Fan","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2024052109592122000_8.1.e000579.22","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0141-4"},{"key":"2024052109592122000_8.1.e000579.23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10067-019-04856-z","article-title":"Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies","volume":"39","author":"Masson","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2024052109592122000_8.1.e000579.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0428-y"},{"key":"2024052109592122000_8.1.e000579.25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/ehjcvp\/pvz033","article-title":"Lipid management in rheumatoid arthritis: a position paper of the Working group on cardiovascular pharmacotherapy of the European Society of cardiology","volume":"6","author":"Hollan","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024052109592122000_8.1.e000579.26","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2017-000212","article-title":"Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us?","volume":"4","author":"Boulos","year":"2017","journal-title":"Lupus Sci Med"},{"key":"2024052109592122000_8.1.e000579.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.4832"},{"key":"2024052109592122000_8.1.e000579.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775"},{"key":"2024052109592122000_8.1.e000579.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.113696"},{"key":"2024052109592122000_8.1.e000579.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00114-3"},{"key":"2024052109592122000_8.1.e000579.31","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2024052109592122000_8.1.e000579.32","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht108"},{"key":"2024052109592122000_8.1.e000579.33","article-title":"Characteristics of antiphospholipid antibody positive patients in antiphospholipid syndrome alliance for clinical trials and international networking","author":"Sevim","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2024052109592122000_8.1.e000579.34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.semarthrit.2017.10.015","article-title":"Carotid and femoral atherosclerosis in antiphospholipid syndrome: equivalent risk with diabetes mellitus in a case\u2013control study","volume":"47","author":"Kravvariti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2024052109592122000_8.1.e000579.35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/acr.23574","article-title":"Lipid testing and statin prescriptions among Medicaid recipients with systemic lupus erythematosus or diabetes mellitus and the general medicaid population","volume":"71","author":"Chen","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2024052109592122000_8.1.e000579.36","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/rheumatology\/kew497","article-title":"Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the implementation of cardiovascular risk management in rheumatoid arthritis project","volume":"56","author":"van den Oever","year":"2017","journal-title":"Rheumatology"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2021-000579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:59:37Z","timestamp":1716310777000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2021-000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12,17]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/lupus-2021-000579"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2021-000579","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}